SynthesisJournal of Alzheimer's disease : JAD2025
Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis.
Synthesis in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis.Frontiers in endocrinology · 2026 · on this mapPooled it
- Systemic medications and dementia risk: a systematic umbrella review.Molecular psychiatry · 2025Pooled it
- Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Metformin Use Is Associated With Better Cognitive Performance in Older Adults With Type 2 Diabetes: Exploratory Analysis of Vitamin B12 and Methylmalonic Acid Pathways in NHANES 2011-2014.Diabetes, obesity & metabolism · 2026Article
- Timing matters: a life-course review of midlife type 2 diabetes, exposure duration, and late-life dementia risk.Journal of diabetes and metabolic disorders · 2026Review
- Association of GLP-1 receptor agonist use with mortality and healthcare utilization in patients with vascular dementia.Acta neurologica Belgica · 2026Article
- Glucose-Lowering Therapies and Cognitive Decline: From Molecular Mechanisms to Clinical Evidence and Future Perspectives.Advances in therapy · 2026Review
- Glucagon-like peptide-1 receptor agonists and cognitive function: beyond the metabolic effects.Hormones (Athens, Greece) · 2026Article
- The Interaction Between Insulin Resistance and Neuroinflammation in the Brain and Its Impact on Diabetic Encephalopathy.Biology · 2026Review
- Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulation.GeroScience · 2026Article
- Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions.Communications medicine · 2026Article
- Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for incident dementia: A retrospective multicohort study.Diabetes, obesity & metabolism · 2026Article
- Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.Pharmaceutics · 2026Review
- Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study.PloS one · 2026Article
- Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework.Frontiers in aging neuroscience · 2026Review
- Prions and protein aggregates as pathogens, self-propagating structures, biomarkers, and therapeutic targets.Microbiology and molecular biology reviews : MMBR · 2025Review
- Adipokines at the Metabolic-Brain Interface: Therapeutic Modulation by Antidiabetic Agents and Natural Compounds in Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Association between serum lactoferrin concentrations and the prevalence of mild cognitive impairment among Chinese adults: a cross-sectional study.European journal of nutrition · 2025Article
- Recent advances in incretin-based therapy for the treatment of cognitive impairment associated to the type 2 diabetes mellitus: preclinical and clinical studies - a narrative review.Frontiers in endocrinology · 2025Review
- Strategies for Person-Centered Comprehensive Diabetes Management in Older Adults With Cognitive Impairment.Diabetes, obesity, and cardiometabolic CAREReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.